ArticleFrontiers in allergy2026
Prioritizing extracellular miRNA candidates in asthma: transparent
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracellular microRNAs (miRNAs) are promising asthma biomarker candidates, but database-derived panels require literature assessment. Objective: To prioritize extracellular asthma-associated miRNAs and evaluate literature-based concordance, specificity and target-network structure. Methods: RNADisease v4.0, miEAA, miRPathDB 2.0, miRDB v6.0, MSigDB v7.4 C3 MIR:MIRDB, Reactome, and Gene Ontology were integrated. Formal concordance required an exact mature-arm identifier and a clearly interpretable asthma contrast in a separate published human extracellular-miRNA study; arm-unspecified names were retained only as contextual evidence. Predicted targets were analyzed using unique MIR:MIRDB target-set counting, Reactome over-representation testing, and Benjamini-Hochberg correction across 1,217 pathways. Results: Sixty-three extracellular candidates were identified; 60 had an EV/exosome/microvesicle annotation and 53 had at least two localization/transport annotations. Three published studies supported six formally concordant candidates, while four additional candidates had only arm-unspecified contextual support. GSE280322 showed no exact mature-arm overlap. Raw-read reprocessing was feasible but not undertaken; this represented published-result concordance rather than sample-level validation. Fifty-nine candidates mapped to 57 unique target sets and 7,092 genes; four were unmapped, including formally concordant hsa-miR-126-3p, so concordance and network sets were non-identical. The analysis yielded 108 hubs and one FDR-significant, parameter-contingent Reactome pathway: regulation of MECP2 expression and activity. Conclusion: This framework supports prioritization, but no validated or asthma-specific signature was established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.